[ Price : $8.95]
Adverse event reports associated with blood thinners Pradaxa (dabigatran) and warfarin top the list of drug safety problems report...[ Price : $8.95]
MiMedx Group and FDA reschedule a meeting to discuss a recent Untitled Letter the firm received requiring it to obtain a BLA to la...[ Price : $8.95]
FDA approves an Actelion Pharmaceuticals NDA for Opsumit (macitentan) for treating pulmonary arterial hypertension to delay diseas...[ Price : $8.95]
Ariad Pharmaceuticals stops its Phase 3 EPIC trial involving Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid ...[ Price : $8.95]
AdvaMed says FDA should send future considerations and other concerns about an IDE-approved clinical trial to sponsors in separate...[ Price : $8.95]
FDA sends pSivida another complete response letter on a resubmitted NDA for Iluvien (fluocinolone acetonide) for treating chronic ...[ Price : $8.95]
Boston Scientific and its Guidant subsidiary agree to pay $30 million to settle government allegations that Guidant knowingly sold...[ Price : $8.95]
Washington Legal Foundation says an FDA proposed guidance on medical device reporting imposes new requirements on manufacturers th...